1/8 Most influential stewardship papers presented at #IDWeek2022. 1. Women in rural settings MORE LIKELY to get antibiotic treatment for uncomplicated UTI for a duration longer than recommended by guidelines, compared with urban settings. pubmed.ncbi.nlm.nih.gov/33622432/
2/8 Why does this matter? "Each day of antibiotic therapy was associated with 4% increased odds of experiencing an adverse event." pubmed.ncbi.nlm.nih.gov/34775072/
3/8 ED specific urine antibiogram, UTI guideline, education, department specific feedback followed by re-education & provider specific feedback -> initial 15% improvement in guideline-concordant abx followed by additional 3% improvement Q2wks during study. pubmed.ncbi.nlm.nih.gov/35100621/
4/8 Seven month remote telehealth prospective audit and feedback, guideline and order set management, and staff education -> 63% reduction carbapenem, 20% reduction FQ, 18% reduction vanco, 9% reduction LOS. All lost when contract not renewed. pubmed.ncbi.nlm.nih.gov/34153104/
5/8 "ASPs with successful reductions in consumption of targeted antibiotics may not see changes in infection rates with antibiotic-resistant organisms in the 2 to 6 years post-implementation." But things also didn't get worse. pubmed.ncbi.nlm.nih.gov/32667983/
6/8 Opt-Out Protocol for Antibiotic De-escalation in Patients with Suspected Sepsis -> "more antibiotic discontinuations, similar DOT when antibiotics were continued, and no evidence of harm." pubmed.ncbi.nlm.nih.gov/36167851/
7/8 Fantastic machine-human collaboration. Machine learning approach reduced prospective audit & feedback reviews in half with good sensitivity on the cases left to review. A clinical pharmacist on the unit or a formal ID consult reduced utility of PAF. pubmed.ncbi.nlm.nih.gov/35873287/
8/8 Seven days equivalent to 14 days for GNR bacteremia, INCLUDING with discharge from ED on oral therapy. pubmed.ncbi.nlm.nih.gov/34508886/
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/10 Most influential infection prevention papers presented at #IDWeek2022 (non-COVID). 1. In >300 HCP caring for monkeypox patients, only 23% wore all recommended PPE, yet no HCP infections in 21 days. Risk of transmission in health care settings is low. pubmed.ncbi.nlm.nih.gov/36136939/
2/10 Near ZERO viral detection when swabbing nostrils of HCWs exposed to a nebulized virus in a sealed clinical room for 40 mins wearing a fit-tested N95 (that passed) plus HEPA filtration. Wearing a non-fit-tested or failed fit-tested N95 not protective. pubmed.ncbi.nlm.nih.gov/35535021/
3/10 "In patients with symptom resolution of C. difficile infection AFTER treatment with standard-of-care antibiotics [PO Vanco or Fidaxomicin), oral administration of SER-109 was superior to placebo in reducing the risk of recurrent infection." pubmed.ncbi.nlm.nih.gov/35045228/
"Machine learning-based clinical decision support tools for sepsis create opportunities to identify at-risk patients and initiate treatments at early time points." 89% of ~9800 alerts reviewed by physician/APP over 2 yrs -> 2hr less time to 1st abx. pubmed.ncbi.nlm.nih.gov/35864251/
Clinical trials in bacterial diseases that may change your practice. #IDWeek2022 1. De-escalation of antibiotics for VAP based on Gram stain was non-inferior to waiting for culture. pubmed.ncbi.nlm.nih.gov/35394515/
2. Obtaining follow-up blood cultures in patients with Gram negative bacteremia associated with decreased mortality. pubmed.ncbi.nlm.nih.gov/36136334/
3. SABATO trial presented at ECCMID 2022. Oral switch to Bactrim 1 DS PO BID (or clindamycin 600mg PO Q8hr or linezolid 600mg PO BID) non-inferior to IV course for Staph aureus bacteremia secondary to venous catheter or skin and soft tissue infection. clinicaltrials.gov/ct2/show/NCT01…
Although @IDSAInfo 10 by ‘20 initiative resulted in 14 new ID drugs coming to market, “the majority…have been modifications of existing chemical classes of antibiotics [and] larger pharmaceutical companies continue to abandon the field.” Nobody’s buying. pubmed.ncbi.nlm.nih.gov/30715222/
“The antibiotic market is broken and won’t fix itself,” says @hboucher3 at #IDWeek2022.
1/4 Dr. Klompas presented at #IDWeek2022 on a big change in the @SHEA_Epi Compendium for VAP Prevention. STOP oral care with chlorhexidine and switch to oral care with toothbrushing. pubmed.ncbi.nlm.nih.gov/35589091/
2/4 Data from double-blind RCTs doesn't show lower VAP rates with chlorhexidine oral care, there is no reduction in ICU length of stay or duration of mechanical ventilation, and there is concern about higher mortality. pubmed.ncbi.nlm.nih.gov/24663255/, pubmed.ncbi.nlm.nih.gov/24687313/
3/4 Risk may be from increased oral health dysfunction with chlorhexidine which can be caustic to oral mucosa. pubmed.ncbi.nlm.nih.gov/34609548/ Dr. Klompas also discussed potential ARDS related to aspiration of chlorhexidine.
1/8 Let's talk New Hampshire. We need to have an honest dialogue about how bad things are right now with #COVID19. We currently are averaging more cases per day than at any point in the pandemic (66x higher than last summer). @SteveAhnen@NHHospitals@NHMedSociety@DartmouthHitch
2/8 The PCR positivity rate is back to where it was in April 2020, with 3 counties/cities reporting PCR positivity rates >15% (Coos, Sullivan, Nashua) and some clinics in the south of the state are at 25%. As this increases, true >> reported infections.
3/8 The entire state of NH is at substantial levels of community transmission. In fact, we are currently 10x higher than the level that determines substantial transmission, with Sullivan Country 18x higher.